H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $30.00. The company’s shares closed last Wednesday at $6.14, close to its 52-week low of $3.33.
According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -13.1% and a 35.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.
Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $25.00, implying a 325.2% upside from current levels. In a report issued on July 6, JMP Securities also reiterated a Buy rating on the stock with a $20.00 price target.
Sutro Biopharma’s market cap is currently $288.2M and has a P/E ratio of -2.49.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
Read More on STRO:
- Analyst Explains Why They Downgraded Their Rating on New Relic (NEWR)
- H.C. Wainwright Thinks Vista Gold’s Stock is Going to Recover
- Cowen & Co. Keeps a Buy Rating on Knight Transportation (KNX)
- Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), aTyr Pharma (LIFE) and Aytu BioScience (AYTU)
- Why Are Alcoa Shares Trending Higher?